curacle
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Curacle is a South Korean biotech company listed on KOSDAQ that develops experimental medicines targeting a root cause of hard-to-treat diseases: the breakdown of the cells lining blood vessels, known as endothelial dysfunction.
Its lead candidate, Rivasterat, is an oral drug being developed for retinal diseases such as diabetic macular edema and wet macular degeneration. The company builds its pipeline through two proprietary drug-discovery platforms, one for small-molecule chemical drugs (SOLVADYS®) and one for biologics (EAGLES®).
Summary is AI-generated and may contain errors · figures from DART filings
curacle in five facts
What does curacle do?
Curacle is a South Korean biotech company listed on KOSDAQ that develops experimental medicines targeting a root cause of hard-to-treat diseases: the breakdown of the cells lining blood vessels, known as endothelial dysfunction.
Where is curacle listed and in which sector?
curacle (Korean name: 큐라클) trades under KRX code 365270 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Commercial Services.
How large is curacle?
Its market capitalisation was US$152.2M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were curacle's latest annual revenue and operating profit?
For fiscal year 2025, curacle reported revenue of US$5.4K, an operating loss of US$12.5M and a net loss of US$13.7M, per its annual report on DART (data retrieved from DART on 2026-06-03). Revenue was down 99.6% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-06-03
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
curacle reported separate results for FY2025: revenue of US$4.86K (−99.5% year on year), an operating loss of US$11.3M and a net loss of US$12.2M.
Earnings · Feb 9 - [Amended] Material event report (merger)M&A · Feb 6
- Completion report on merger, etc. (merger)M&A · Feb 2
- [Amended] Material event report (merger)M&A · Jan 29